PositioningFocused on developing innovative immune cell therapy drugs with independent intellectual property rights, our main focus is on the treatment and prevention of recurrence of solid tumors, as well as the research and development of drugs for autoimmune diseases.
State-recognizedUndertake the "double" special project of 2025 super long treasury bond, and participate in the special sub project of the national key research and development plan (application demonstration of immune cell therapy).
MissionSatisfy unmet clinical needs and make high-quality and accessible cell therapies a reality.
Cytocraft Biopharmaceutical Co., Ltd. was established by well-known domestic biopharmaceutical R&D experts and industrialization experts, focusing on the development of innovative immune cell therapy drugs with independent intellectual property rights. Its main focus is on the treatment and prevention of recurrence of solid tumors, as well as the research and development of drugs for autoimmune diseases. It has first-class research results and dozens of patented technologies in China.
The company undertook the 2025 super long treasury bond "dual" special project in the field of biological manufacturing (direction of cell therapy technology), and participated in the research of the special sub project of the 2023 national key research and development plan (application demonstration of immune cell therapy).
Cytocraft Biotech focuses on the field of anti solid tumor cell therapy and has built non genetically modified SDT-T and SDT-M immune cell technology platforms, as well as genetically modified UCAR-T immune cell technology platform. It has a B+A-level R&D and production laboratory that meets the GMP requirements for cell therapy products, a CMA+CNAS certified quality inspection laboratory, and holds three IND approvals for cell class I new drugs for solid tumor treatment.
2017+
Established in 201750+
Dozens of technical patents3+
Multi technology platform7+
product pipeline
Beijing Hospital
High tech enterprises
National-level technology-based
Innovative enterprise in Sichuan Province
Innovative Small and Medium sized Enterprises
Zhongguancun High tech Enterprise
Chengdu’s new economy gradient
New economy gradient enterprises in Jinniu District
Intellectual Property Management SystemCertified Enterprise
Integration of informatization and industrialization management
National technology-based enterprise
T/ZGCIT067-2025 – Main Compilation Unit of Group Standards
T/ZGCITO68-2025 – Main Compilation Unit of Group Standard
Chengdu Enterprise Technology Center
Innovative Small and Medium sized Enterprises in Beijing
Chengdu Enterprise Technology Center
Professional Committee for Quality Control and Research of Cell Therapy
MA-Qualification Certificate of Testing Organization
CNAS – China National Accreditation Service
Cancer Hospital, Chinese Academy of Medical Sciences
Peking Union Medical College Hospital
Union Hospital Wuhan
The First Affiliated Hospital of Zhengzhou University
Shandong Provincial Hospital
The Third Affiliated Hospital of Kunming Medical University
Beijing Friendship Hospital, Affiliated to Capital Medical University
Army Medical University Xinqiao Hospital
Focus Focusing on clinical efficacy and accessibility of cellular therapy Focusing on solid tumors and autoimmune diseases, we are committed to developing cutting-edge cell therapies and optimizing processes to reduce costs and improve drug accessibility.
Focus focus Focusing on clinical efficacy and accessibility of cellular therapy
Expand Expand the field of longevity medicine Expand the therapeutic boundary of immune cell therapy around the three directions of "clearing aging cells, restoring immune homeostasis, and reducing chronic inflammation".
Expand expand Expand the field of longevity medicine
Platform Building an integrated platform Building a complete industrial closed loop integrating research and development, production, and transformation, promoting the transition of cell drugs from the laboratory to clinical applications, and benefiting a wide range of patients.
Platform platform Building an integrated platform
WeChat QR code
This website uses cookies to provide you with a personalized browsing experience and analyze website traffic. By clicking 'Accept', you agree to our use of cookies.
Global